Guojun Wang1, Dawei Dai2, Xin Chen2, Lei Yuan2, Aijun Zhang2, Youming Lu2, Pengqi Zhang2. 1. Department of Neurosurgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital Shanghai, China ; Department of Neurosurgery, Central Hospital of Tai'an Tai'an, Shandong Province, China. 2. Department of Neurosurgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital Shanghai, China.
Abstract
BACKGROUND: Peripheral nerve injury can result in neuropathic pain, a chronic condition of unclear cause often poorly responsive to current treatments. One possibility is that nerve injury disrupts large A-fiber-mediated inhibition of C-fiber-evoked responses in spinal dorsal horn neurons, leading to central sensitization. A recent study provided a potential molecular mechanism; large dorsal root ganglion (DRG) neurons secrete neuregulin-1 (NRG1), which binds to erbB4 receptors on interneurons and promotes GABA release to inhibit C-fiber-evoked nociceptive transmission. Thus, reduced NRG1 expression following nerve injury could induce chronic pain by disinhibition. We examined if DRG expression of NRG1 is in fact reduced in a rat model of neuropathic pain and if exogenous NRG1 alleviates behavioral signs of this condition. METHODS: Three neuropathic pain models were established in rats: spared nerve injury of the tibial and common peroneal nerves (SNI model), intraplantar injection of complete Freund's adjuvant (CFA model), and subcutaneous formalin injection. NRG1 expression was assessed by immunofluorescent staining, hyperalgesia by paw withdrawal threshold to von Frey filament stimulation, and pain-like behavior by spontaneous flinching. RESULTS: NRG1 protein immunoreactivity was reduced in the rat DRG after SNI. Intrathecal administration of neuregulin-1beta 1 (NRG1-1), a 62 amino acid NRG1 mimetic, transiently increased paw withdrawal threshold in SNI model and reduced flinching in the formalin injection model. CONCLUSION: Our results are consistent with a model of neuropathic pain whereby peripheral nerve injury reduces NRG1-mediated inhibition of nociceptive signaling. Modulating NRG1 may have therapeutic potential for treating neuropathic pain.
BACKGROUND: Peripheral nerve injury can result in neuropathic pain, a chronic condition of unclear cause often poorly responsive to current treatments. One possibility is that nerve injury disrupts large A-fiber-mediated inhibition of C-fiber-evoked responses in spinal dorsal horn neurons, leading to central sensitization. A recent study provided a potential molecular mechanism; large dorsal root ganglion (DRG) neurons secrete neuregulin-1 (NRG1), which binds to erbB4 receptors on interneurons and promotes GABA release to inhibit C-fiber-evoked nociceptive transmission. Thus, reduced NRG1 expression following nerve injury could induce chronic pain by disinhibition. We examined if DRG expression of NRG1 is in fact reduced in a rat model of neuropathic pain and if exogenous NRG1 alleviates behavioral signs of this condition. METHODS: Three neuropathic pain models were established in rats: spared nerve injury of the tibial and common peroneal nerves (SNI model), intraplantar injection of complete Freund's adjuvant (CFA model), and subcutaneous formalin injection. NRG1 expression was assessed by immunofluorescent staining, hyperalgesia by paw withdrawal threshold to von Frey filament stimulation, and pain-like behavior by spontaneous flinching. RESULTS:NRG1 protein immunoreactivity was reduced in the rat DRG after SNI. Intrathecal administration of neuregulin-1beta 1 (NRG1-1), a 62 amino acid NRG1 mimetic, transiently increased paw withdrawal threshold in SNI model and reduced flinching in the formalin injection model. CONCLUSION: Our results are consistent with a model of neuropathic pain whereby peripheral nerve injury reduces NRG1-mediated inhibition of nociceptive signaling. Modulating NRG1 may have therapeutic potential for treating neuropathic pain.
Authors: Margarita Calvo; Ning Zhu; Christoforos Tsantoulas; Zhenzhong Ma; John Grist; Jeffrey A Loeb; David L H Bennett Journal: J Neurosci Date: 2010-04-14 Impact factor: 6.167
Authors: Walter Kostich; Brian D Hamman; Yu-Wen Li; Sreenivasulu Naidu; Kumaran Dandapani; Jianlin Feng; Amy Easton; Clotilde Bourin; Kevin Baker; Jason Allen; Katerina Savelieva; Justin V Louis; Manoj Dokania; Saravanan Elavazhagan; Pradeep Vattikundala; Vivek Sharma; Manish Lal Das; Ganesh Shankar; Anoop Kumar; Vinay K Holenarsipur; Michael Gulianello; Ted Molski; Jeffrey M Brown; Martin Lewis; Yanling Huang; Yifeng Lu; Rick Pieschl; Kevin O'Malley; Jonathan Lippy; Amr Nouraldeen; Thomas H Lanthorn; Guilan Ye; Alan Wilson; Anand Balakrishnan; Rex Denton; James E Grace; Kimberley A Lentz; Kenneth S Santone; Yingzhi Bi; Alan Main; Jon Swaffield; Ken Carson; Sandhya Mandlekar; Reeba K Vikramadithyan; Susheel J Nara; Carolyn Dzierba; Joanne Bronson; John E Macor; Robert Zaczek; Ryan Westphal; Laszlo Kiss; Linda Bristow; Charles M Conway; Brian Zambrowicz; Charles F Albright Journal: J Pharmacol Exp Ther Date: 2016-07-13 Impact factor: 4.030
Authors: Gregory Livshits; Ida Malkin; Maxim B Freidin; Yudong Xia; Fei Gao; Jun Wang; Timothy D Spector; Alex MacGregor; Jordana T Bell; Frances M K Williams Journal: Pain Date: 2017-06 Impact factor: 6.961
Authors: Lucas Topham; Stephanie Gregoire; HyungMo Kang; Mali Salmon-Divon; Elad Lax; Magali Millecamps; Moshe Szyf; Laura S Stone Journal: Pain Date: 2020-10 Impact factor: 7.926